Breathe Well Live Well
Drug Discovery & Development |
Asmacure Posts Promising Phase 1/2a Asthma Drug Results
Drug Discovery & Development "The pharmacokinetics data from this study provided important information on the potential dose range for ASM-024 in the treatment of the moderate asthma patient when delivered as a dry powder for inhalation." ASM-024 is under development in a dry … |
View full post on asthma – Google News
|
Amgen Posts Positive Phase I Results For Asthma Drug
BioResearch Online (press release) Amgen reported positive results from the Phase I study showing that inhibiting thymic stromal lymphopoietin (TSLP) could be useful in the treatment of asthma. TSLP is a cytokine considered to be a key driver of the allergic inflammation that … Anti-thymic stromal lymphopoietin therapy reduced allergy-induced … |
View full post on asthma – Google News
|
MedImmune to present Phase IIb asthma data on benralizumab and …
News-Medical.net In the Phase IIb data being presented, both benralizumab and tralokinumab show promising safety and efficacy outcomes, suggesting they may offer important new therapeutic options for patients with specific forms of severe, uncontrolled asthma. |
View full post on asthma – Google News
Condition: Asthma
Intervention: Biological: Mepolizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified May 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
Drug Discovery & Development Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the … Tiotropium as Asthma Add-On Treatment Shows Promise |
View full post on asthma – Google News
|
Atopix reports positive results from Phase IIb asthma study with OC459 compound
News-Medical.net Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
PR Newswire (press release) RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ — Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, … |
View full post on asthma – Google News
|
Phase III studies show tiotropium delivered via Respimat inhaler proves …
News-Medical.net Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News
|
ASTHMA: New Phase III data show tiotropium * Respimat ® effective across …
Business Wire (press release) Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News
|
KaloBios calls it quits on its asthma drug after a Phase II flop
FierceBiotech San Francisco's KaloBios ($KBIO) is hitting the breaks on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company's shares into a 30% tailspin. The drug, KB003, failed to significantly … KaloBios Pharma pulls plug on asthma drug, shares plunge KaloBios stock slides; to stop asthma study KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma Study |
View full post on asthma – Google News